Radioactive treatment for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a radioactive treatment (177Lu-PSMA-VG01) that targets a protein called PSMA on prostate cancer cells. It's for men whose cancer has spread and hasn't gotten better with other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- Your prostate cancer has spread and no longer responds to standard treatments.
- You must have at least one spot of cancer that shows up on a scan (like a PSMA PET scan).
- You should be able to care for yourself and be expected to live at least 6 more months.
- You need to use condoms during sex and not donate sperm during the study and for 14 weeks after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that targets a protein called PSMA found on prostate cancer cells. It uses a radioactive form of the treatment to try to kill cancer cells while limiting damage to healthy cells. This study is for men with advanced prostate cancer that has stopped responding to other treatments.
This early-phase study tests a new radioactive drug that targets PSMA, a protein on prostate cancer cells, to see if it can shrink tumors and slow the disease. It may be an option for men with advanced prostate cancer that has not responded to hormone therapy and possibly chemotherapy.
This is an early-stage trial testing a new radioactive treatment (161Tb-PSMA) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The treatment targets cancer cells using a radioactive metal that may be more effective than older similar treatments.
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
This study tests a new radioactive drug (177Lu-PSMA-137) that targets a marker on prostate cancer cells called PSMA. It aims to see if this treatment is safe and effective for men with advanced prostate cancer that has spread and stopped responding to standard treatments.
Hear when a new PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.